{"id":"W3007860954","doi":"10.1200/jco.2020.38.6_suppl.484","title":"An open-label, multicenter, phase IIIb study of patients with urinary tract carcinoma (UTC) (STRONG): Interim safety results for fixed-dose durvalumab (D) monotherapy (module A).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Durvalumab; Urology; Discontinuation; Chemotherapy; Internal medicine; Interim analysis; Clinical endpoint; Adverse effect; Oncology; Gastroenterology; Surgery; Cancer; Clinical trial; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003544613,0.001399218,0.001415161,0.0003212552,0.0004140841,0.0007356682,0.0008942965,0.001121773,0.0040631],"category_scores_gemma":[0.001323659,0.0005400126,0.00117304,0.0003844379,0.000589238,0.0007322287,0.0004276196,0.002145862,0.001238334],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006912592,"about_ca_system_score_gemma":0.001598651,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005465814,"about_ca_topic_score_gemma":0.001358428,"domain_scores_codex":[0.9989918,0.0006703984,0.00003727765,0.0001070407,0.00008587979,0.0001076891],"domain_scores_gemma":[0.9982857,0.0003198403,0.0004156407,0.0001731885,0.0001134556,0.0006921529],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7944685,0.06347997,0.02963823,0.0008019952,0.002806719,0.0002238702,0.0002675595,0.001967019,0.03063604,0.0002425658,0.009618501,0.06584911],"study_design_scores_gemma":[0.6026893,0.3499753,0.03871293,0.00003265042,0.0006985834,0.0002775216,0.0000412396,0.00124426,0.002400835,0.0001845932,0.003709604,0.00003327502],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9878833,0.001309771,0.0009586934,0.0003636999,0.00006296968,0.003758037,0.003750903,0.00009263059,0.001819911],"genre_scores_gemma":[0.9777586,0.0009101095,0.003522898,0.001306004,0.0001620566,0.005129422,0.008551327,0.00004742998,0.002612131],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0040631,"threshold_uncertainty_score":0.01874596,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2018032204561469,"score_gpt":0.4996626713896408,"score_spread":0.297859450933494,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}